RZLT - Rezolute started at overweight at Cantor on potential of rare low blood sugar treatment

Cantor Fitzgerald has initiated Rezolute (NASDAQ:RZLT) at overweight citing the company's lead candidate RZ358 for congenital hyperinsulinism as it could be a more than $500M revenue generator by 2030. The firm has a $9 price target (197% upside based on Tuesday's close). Analyst Pete Stavropoulos said that RZ358 could become a cornerstone in the treatment of the condition. And because congenital hyperinsulinism -- which causes low blood sugar leading to brain damage and developmental delays in children -- is a rare disease, it could make it easier for the candidate to be priced at top dollar. RZ358 has Orphan Drug Designation from the U.S. FDA. Stavropoulos added that existing phase 2b data is likely to help RZ358 gain Breakthrough Therapy Designation as well. He expects Rezolute (RZLT) to announce a registrational trial program in the second half of the year followed by trial initiation in 1Q 2023. Stavropoulos noted that the

For further details see:

Rezolute started at overweight at Cantor on potential of rare low blood sugar treatment